CAR-T Failure in DLBCL: The Next Step
Why CAR-T Fails and How to Respond
CD19-targeted CAR T-cell therapy has become a standard second-line option for diffuse large B-cell lymphoma. Three FDA-approved products now treat this aggressive cancer. Despite success, many patients relapse or fail to respond.
Health news
Exercise and Mood: Italian Study Links Physical Activity to Lower Depression Symptoms
Screen Time in Childhood Linked to Unexpected Cognitive Boost in Teens, 8‑Year Study Shows
Workplace stress and anxiety are taking a heavy toll on employees, with one in three workers reporting that the strain is not easing
Daily Food Habit Tied to Lower Risk of Anxiety and DepressionClinicians must now decide the next course of action. The decision hinges on the reason for failure. A patient who never responded differs from one who relapsed after initial remission.
Alex Herr, a leading expert, notes that durable responses occur in only 30% to 40% of patients. This means a majority do not achieve long-term control. Understanding the mechanism of failure guides the next treatment choice.
What Should Patients Ask Their Doctor?
If the tumor lacks CD19 expression, switching to a different target makes sense. If the T-cells are exhausted, supportive care or a different modality is needed. Clinical trials are exploring combinations with checkpoint inhibitors or bispecific antibodies.
Patients facing CAR-T failure should ask about the specific reason for the lack of response. They should also inquire about clinical trials testing new combinations. Understanding the biology of their relapse helps target the next therapy.
Frequently Asked Questions
What percentage of DLBCL patients achieve durable remission with CAR-T? About 30% to 40% of patients see ongoing responses. The rest either relapse or never respond initially.
What is the most common reason for CAR-T failure in DLBCL? Loss of CD19 expression on tumor cells is a frequent cause. T-cell exhaustion and immune suppression also contribute significantly.
Are there new treatments being tested after CAR-T failure? Yes. Clinical trials are testing combinations with checkpoint inhibitors, bispecific antibodies, and novel CAR designs targeting different antigens.